Predictors of Survival Outcomes in Non-Metastatic Renal Cell Carcinoma in Latin America and Spain: A Multicentric Analysis

Zéqui, Stênio de Cássio; Mourão, Thiago Camelo; Oliveira, Max Moura de; Curado, María Paula; Gueglio, G.; Costa, Walter Henriques da; Zúñiga, Álvaro; Bengió, Rubén H.; Scorticati, Carlos H.; Rodríguez, Francisco Javier García; Autran, Ana Maria; Martinez, Pablo Elías; Ameri, Carlos; Mingote, Pablo; Secín, Fernando P.; Decia, Ricardo; Cunha, Isabela Werneck da; Guimarães, Gustavo Cardoso; Glina, Sidney; Palou, Joan; Abreu, Diego

doi:10.3233/kca-190068

Cited by 8 publications

(6 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A multi-institutional large retrospective study of 5670 patients over 36 years who underwent radical or partial nephrectomy from seven Latin American countries and Spain reported by Zequi et al found the 5-year survival for RCC to be 86.1%. 22 The five-year survival rate of our study was 62.8%, which is lower than the survival rate mentioned above. About 26.2% of the cases were diagnosed with metastatic disease, and a further 6% progressed to metastatic cancer despite surgical resection.…”

Section: Discussioncontrasting

confidence: 72%

Epidemiological and Histopathological Characteristics of Renal Cell Carcinoma in Somalia

Mohamed¹,

Abdullahi²,

Eraslan³

et al. 2022

CMAR

View full text Add to dashboard Cite

Background There is a scarcity of studies regarding renal cell carcinoma (RCC) reported from Sub-Saharan Africa. Objective The present study is the first report evaluating the prevalence and clinical and histopathological features of RCC at a tertiary hospital in Somalia. Methods This retrospective study included 84 patients with histologically confirmed RCC over 5-years. The investigated parameters were sociodemographic features, radiological and histopathological characteristics, mortality, and overall 5-year survival rate. Results The prevalence of RCC in our study was 0.7%. The mean age of the patients was 53.74±5.5 years, 67.9% were male, and 32.1% were female, with a 2:1 male-to-female ratio. The mean tumor size was 6.38±2.4 cm. Clear cell RCC was the most common histological type in 67.8%, followed by papillary RCC (15.6%), unclassified RCC (9.5%), and chromophobe RCC was the least common in 7.1% of the cases. About one-third of the case had locally advanced RCC with positive nodal involvement, 26.2% of the patients had metastatic disease, and a further 6% progressed to metastatic cancer despite surgical resection. Eight percent of our cases returned with local recurrence. The mortality rate was 37.2%. More than eighty percent of females had a low-stage and a low-grade RCC, while males held higher stages and higher grades RCC in 37% and 63%, respectively (p<0.001). Smokers were male-only, while obesity was common in female patients (p=0.02). Conclusion The study findings showed a satisfactory outcome, 71.4% of our patients presented with localized RCC, the five-year survival rate of the patients was 62.8%, and the mortality rate was substantially higher for patients with a higher stage, a higher grade tumor, and metastatic disease at the time of diagnosis.

show abstract

Section: Discussioncontrasting

confidence: 72%

Epidemiological and Histopathological Characteristics of Renal Cell Carcinoma in Somalia

Mohamed¹,

Abdullahi²,

Eraslan³

et al. 2022

CMAR

View full text Add to dashboard Cite

show abstract

“…CCRCC is the most common subtype and PRCC is the second most common subtype in RCC. ChRCC accounts for 4-6% of all RCC 4 . Diagnosis of cases were 78,8% CCRCC, 15,1% PRCC and 6,1% ChRCC in this study.…”

Section: Discussionmentioning

confidence: 99%

“…Sağkalım ile yaş ve tümör çapı arasında ters ilişki bulunmaktadır 3 . Metastatik lenf nodu, tümör nekrozu ve çevre yağ doku invazyonu kötü prognoz ile ilişkilidir 4 . Bu çalışmaya 179 renal hücreli karsinom vakası dahil edildi.…”

Section: öZunclassified

See 1 more Smart Citation

Pathological Prognostic Features and Analysis of Renal Cell Carcinoma

ÖZTÜRK¹,

ÇELİKGÜN²,

Yeldir³

2022

CMJ

View full text Add to dashboard Cite

Renal cell carcinomas is 2-3% of all adult cancers. Kidney cancer is currently the seventh most common cancer in men and the tenth most common in women (1). There were 19,3 million new cancer diagnoses and 10 million cancer deaths worldwide in 2020 (2). Survival in renal cell carcinomas has a strong correlation with the stage of diagnosis. 5-year survival in stage 1 tumors is 93%, 72,5% in cases with local lymph node metastases and 12% in metastatic carcinomas cases (3). There is an inverse correlation between age / tumor size and survival. Metastatic lymph node, tumor necrosis and adipose tissue invasion are associated with poor prognosis (4). The study is including 179 renal cell carcinoma cases. The clinical and pathological datas of these cases were retrospectively analyzed from the Cumhuriyet University Hospital patient system. The distribution sex of cases are 111 males (62%) and 68 females (38%). The mean age of the 179 cases was 58,5±11,9 years (range of 21-90). The mean tumor diameter is 5,7±3,4 (range of 1-19 cm). The nuclear grades of cases are 53,1% with low grade and 46,8% with high grade. Radical nephrectomies were evaluated for vascular invasion, ureter invasion, capsule/adipose tissue invasion, lymph node metastasis and adrenal gland metastasis. There is a statistically significant relationship between nuclear grade and vein invasion, microvascular invasion, capsule/adipose tissue invasion (p

show abstract

“…While small and localized tumors have a high 5-year relative survival rate at 93%, it drops down significantly when metastases develop to only 12% [6]. Due to the fact that about a third of RCCs are diagnosed at IV (metastatic) stage and 20-50% of pre-metastatic cases will progress to stage IV regardless of surgical excision, the RCC is considered the deadliest urological cancer [7]. The most common type of RCC at 75% occurrence rate is clear cell RCC (ccRCC), followed by papillary RCC (16%) and chromophobe RCC (7%).…”

Section: Rcc -A Brief Overviewmentioning

confidence: 99%

Interleukin 17 and Its Involvement in Renal Cell Carcinoma

Jarocki¹,

Karska²,

Kowalski³

et al. 2022

Preprint

View full text Add to dashboard Cite

Nowadays molecular and immunological research is essential for the better understanding of tumor cells pathophysiology. The increasing number of neoplasms is taken under ‘the molecular magnifying glass’ therefore it is possible to discover complex relationships between cytophysiology and immune system action. An example could be renal cell carcinoma (RCC) which has deep interactions with immune mediators such as Interleukin 17 (IL-17) - an inflammatory cytokine reacting to tissue damage and external pathogens. RCC is one of the most fatal urological cancer because of its often late diagnosis and poor susceptibility to therapies. IL-17 and its relation with tumors is extremely complex and constitute a recent topic for numerous research. What is worth highlighting is IL-17 dual character in cancer development - it could be pro- as well as antitumorigenic. The aim of this review is to summarize the newest data considering multiple connections between IL-17 and RCC.

show abstract

Predictors of Survival Outcomes in Non-Metastatic Renal Cell Carcinoma in Latin America and Spain: A Multicentric Analysis

Cited by 8 publications

References 38 publications

Epidemiological and Histopathological Characteristics of Renal Cell Carcinoma in Somalia

Epidemiological and Histopathological Characteristics of Renal Cell Carcinoma in Somalia

Pathological Prognostic Features and Analysis of Renal Cell Carcinoma

Interleukin 17 and Its Involvement in Renal Cell Carcinoma

Contact Info

Product

Resources

About